Study Finds Common Antibiotic May Lower Schizophrenia Risk

Research published in the American Journal of Psychiatry indicates that the antibiotic doxycycline may significantly reduce the risk of developing schizophrenia in young individuals. The study, conducted by researchers from the University of Edinburgh, alongside the University of Oulu and University College Dublin, analyzed data from over 56,000 adolescents who received treatment from mental health services in Finland.

The findings reveal that adolescents treated with doxycycline exhibited a 30–35% lower risk of developing schizophrenia in adulthood compared to those prescribed other antibiotics. This suggests a potential new use for an established medication in preventing severe mental illness.

To investigate this protective effect, researchers utilized advanced statistical modeling on extensive health care register data. The study aimed to uncover preventive strategies for schizophrenia, a serious condition that typically manifests in early adulthood, characterized by hallucinations and delusional thoughts.

The researchers hypothesize that doxycycline’s anti-inflammatory properties and its influence on brain development could account for its protective benefits. Doxycycline is widely known for its effectiveness in treating infections and acne. Prior studies have indicated that it may reduce inflammation in brain cells and affect synaptic pruning, a process that refines neural connections. Disruptions in this process have been linked to the onset of schizophrenia.

Further analysis confirmed that the reduced risk associated with doxycycline could not be attributed solely to the treatment of acne or other differences among the adolescents. According to Professor Ian Kelleher, the study’s lead and a professor of Child and Adolescent Psychiatry at the University of Edinburgh, “As many as half of the people who develop schizophrenia had previously attended child and adolescent mental health services for other mental health problems. At present, though, we don’t have any interventions that are known to reduce the risk of going on to develop schizophrenia in these young people. That makes these findings exciting.”

While the observational nature of the study limits the ability to draw definitive conclusions about causality, the results provide a compelling impetus for further investigation into the role of doxycycline and other anti-inflammatory medications in adolescent psychiatric care.

As this research unfolds, it holds promise for potentially altering the landscape of preventive measures available for mental health issues, particularly for youth at risk of severe conditions like schizophrenia.

For further details, the full study can be found in the American Journal of Psychiatry, DOI: 10.1176/appi.ajp.20240958.